KR20110017874A - 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 - Google Patents

오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 Download PDF

Info

Publication number
KR20110017874A
KR20110017874A KR1020107027495A KR20107027495A KR20110017874A KR 20110017874 A KR20110017874 A KR 20110017874A KR 1020107027495 A KR1020107027495 A KR 1020107027495A KR 20107027495 A KR20107027495 A KR 20107027495A KR 20110017874 A KR20110017874 A KR 20110017874A
Authority
KR
South Korea
Prior art keywords
ethoxy
xaa
seq
acid
acetylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020107027495A
Other languages
English (en)
Korean (ko)
Inventor
소렌 오스터가드
산네 몰러 크누드센
제인 스페츨러
라스무스 조르젠센
제이콥 코포이드
Original Assignee
노보 노르디스크 에이/에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노보 노르디스크 에이/에스 filed Critical 노보 노르디스크 에이/에스
Publication of KR20110017874A publication Critical patent/KR20110017874A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020107027495A 2008-05-16 2009-05-18 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제 Withdrawn KR20110017874A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08156360.3 2008-05-16
EP08156360 2008-05-16
EP09154461.9 2009-03-05
EP09154461 2009-03-05

Publications (1)

Publication Number Publication Date
KR20110017874A true KR20110017874A (ko) 2011-02-22

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027495A Withdrawn KR20110017874A (ko) 2008-05-16 2009-05-18 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제

Country Status (12)

Country Link
US (1) US20110275559A1 (cg-RX-API-DMAC7.html)
EP (1) EP2279204A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520847A (cg-RX-API-DMAC7.html)
KR (1) KR20110017874A (cg-RX-API-DMAC7.html)
CN (1) CN102027007A (cg-RX-API-DMAC7.html)
AU (1) AU2009248041B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0912615A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723855A1 (cg-RX-API-DMAC7.html)
IL (1) IL208836A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011845A (cg-RX-API-DMAC7.html)
RU (1) RU2504550C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009138511A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767582B2 (ja) 2009-07-02 2015-08-19 武田薬品工業株式会社 ペプチド及びその用途
US20130040877A1 (en) * 2009-09-18 2013-02-14 Novo Nordisk A/S Long-acting y2 receptor agonists
CN102905722A (zh) * 2009-11-13 2013-01-30 诺沃—诺迪斯克有限公司 长效y2受体激动剂
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2012006566A2 (en) 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
HUE036066T2 (hu) 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
PT3068421T (pt) * 2013-11-15 2019-07-11 Novo Nordisk As Compostos de pyy eletivo e usos dos mesmos
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
RS59026B1 (sr) 2013-11-15 2019-08-30 Novo Nordisk As Selektivna pyy jedinjenja i njihova upotreba
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
KR102393642B1 (ko) 2014-01-17 2022-05-03 리플리겐 코포레이션 크로마토그래피 컬럼 살균
EP3145523A4 (en) * 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
CA2988500A1 (en) * 2015-06-12 2016-12-15 Novo Nordisk A/S Selective pyy compounds and uses thereof
RS64643B1 (sr) 2018-02-02 2023-10-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
TW202535916A (zh) 2018-11-01 2025-09-16 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
MX2022013024A (es) * 2020-04-17 2023-03-15 I2O Therapeutics Inc Analogos del peptido tirosina tirosina (pyy) de accion prolongada y metodos de uso de los mismos.
EP4329812A1 (en) 2021-04-27 2024-03-06 Aardvark Therapeutics Inc. Combination of bitter receptor agonist and gut-signaling compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275207C2 (ru) * 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
AU2004273573B2 (en) * 2003-09-19 2010-04-22 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
JP5638177B2 (ja) * 2004-02-11 2014-12-10 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
MXPA06010345A (es) * 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
AU2005261740A1 (en) * 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Also Published As

Publication number Publication date
WO2009138511A1 (en) 2009-11-19
CN102027007A (zh) 2011-04-20
EP2279204A1 (en) 2011-02-02
RU2010149474A (ru) 2012-06-27
AU2009248041A1 (en) 2009-11-19
MX2010011845A (es) 2010-11-22
BRPI0912615A2 (pt) 2016-01-26
JP2011520847A (ja) 2011-07-21
CA2723855A1 (en) 2009-11-19
RU2504550C2 (ru) 2014-01-20
AU2009248041B2 (en) 2013-10-03
US20110275559A1 (en) 2011-11-10
IL208836A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
KR20110017874A (ko) 오래 작용하는 ｙ２ 및／또는 ｙ４ 수용체 작용제
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5209463B2 (ja) アシル化ｇｌｐ−１化合物
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
KR102255479B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 제약
KR102213907B1 (ko) 인슐린 저항성에 대한 개선된 펩티드 약제
KR102512178B1 (ko) 개선된 펩티드 제약
KR102505628B1 (ko) 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제
JP2007537141A (ja) 新規なｇｌｐ−１化合物
JP2007537142A (ja) アルブミン様物質に結合した新規のｇｌｐ−１類似物
EP2477643A1 (en) Long-acting y2 receptor agonists
BR112012029248B1 (pt) Análogo de glp-1 de fórmula i ou a sua composição, análogo de glp-1 de fórmula viii ou um sal farmaceuticamente aceitável ou a composição do mesmo, composição farmacêutica e uso de um composto
RU2779314C2 (ru) Коагонисты рецепторов глюкагона и glp-1 длительного действия
TW201321015A (zh) 一種新胰高血糖素樣肽類似物、組合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140516

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20141006

WITB Written withdrawal of application